RT Journal Article
T1 Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy
A1 Luque, Jordi
A1 Torres, María Isabel
A1 Aumente, María Dolores
A1 Marín, José
A1 García-Jurado, Gema
A1 González, Rafael
A1 Pascual, Domingo
A1 Guerra Pérez, Natalia
A1 López-Rubio, Fernando
A1 Alvarez-López, Rocío
A1 Arizón, José
A1 Peña, José
AB The aims of this study were to quantify the level of soluble HLA-G in heart transplant patients, to determine the relationship between the sHLA-G levels and the appearance of acute rejection episodes, and to identify the influence of immunosuppressive therapy on sHLA-G levels. Analysis of sHLA-G, measured by enzyme-linked immunosorbent assay in the transplant patients, revealed the existence of two similarly sized groups of patients. One group displayed a significant increase (p < 0.001) in sHLA-G during the first month after transplantation while the other group maintained low levels of the molecule (0–30 ng/ml) throughout the study. The latter group displayed a high incidence of recurrent severe rejection. A significant increase (p < 0.01) in sHLA-G 2 hours after administration of immunosuppressive treatment (mycophenolate mofetil, cyclosporine A/FK506, corticoids) was found. These results suggest that sHLA-G participates in the induction of certain levels of immunological tolerance in these recipients.
PB Elsevier
SN 0198-8859
YR 2006
FD 2006
LK https://hdl.handle.net/20.500.14352/97737
UL https://hdl.handle.net/20.500.14352/97737
LA eng
NO Luque, J., et al. «Soluble HLA-G in Heart Transplantation: Their Relationship to Rejection Episodes and Immunosuppressive Therapy». Human Immunology, vol. 67, n.o 4-5, abril de 2006, pp. 257-63. https://doi.org/10.1016/j.humimm.2006.02.034.
NO Ministerio de Sanidad (España)
DS Docta Complutense
RD 31 dic 2025